There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kura Oncology (KURA – Research Report), Privia Health Group (PRVA – Research Report) and Neurogene (NGNE – Research Report) with bullish sentiments.
Kura Oncology (KURA)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Kura Oncology today and set a price target of $32.00. The company’s shares closed last Tuesday at $20.85, close to its 52-week high of $21.40.
According to TipRanks.com, Benjamin has 0 stars on 0-5 stars ranking scale with an average return of
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $29.23, which is a 58.0% upside from current levels. In a report issued on January 21, Jefferies also maintained a Buy rating on the stock with a $32.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Privia Health Group (PRVA)
In a report released today, Constantine Davides from JMP Securities maintained a Buy rating on Privia Health Group, with a price target of $27.00. The company’s shares closed last Tuesday at $20.31, close to its 52-week low of $19.57.
According to TipRanks.com, Davides has 0 stars on 0-5 stars ranking scale with an average return of
Privia Health Group has an analyst consensus of Strong Buy, with a price target consensus of $32.67, implying a 52.8% upside from current levels. In a report released yesterday, Piper Sandler also assigned a Buy rating to the stock with a $35.00 price target.
Neurogene (NGNE)
In a report issued on January 26, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurogene, with a price target of $31.00. The company’s shares closed last Tuesday at $31.50, close to its 52-week high of $33.25.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
Neurogene has an analyst consensus of Strong Buy, with a price target consensus of $38.00, which is a 18.4% upside from current levels. In a report issued on January 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KURA:
- Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Kura Oncology Announces Private Placement Details
- Kura Oncology Executes Unregistered Equity Securities Sale
- Kura Oncology Secures $150 Million in Private Placement
- Kura Oncology to hold a virtual investor event
